Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable

High-dose chemotherapy is a commonly used form of treatment for patients with myeloma or lymphoma but depends on the availability of peripheral blood stem cells for haemopoietic rescue. The timing of blood stem cell collection after mobilization is variable, which impinges on patient comfort (multiple attendances at collection facility to check circulating… CONTINUE READING